Depression Scale (GDS-15) to quantify depressive symptoms, a short version of the National Eye Institute Visual Function Questionnaire (7-item NEI-VFQ) and a single question from the Short Form Health Survey to assess overall health. To ensure that data collection was standardized across centers, clinicians attended a 1-day training event to improve their understanding of depression and all study procedures. For those who consented, information on date of birth, gender, ethnicity, medical illness, time since vision loss first identified, primary ocular diagnosis, corrected Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution acuity and threshold reading ability (Bailey-Lovie Word Reading Chart) was recorded at the clinic. In line with the large-scale Medical Research Council assessment of older adults study, we adopted the relatively conservative cutoff score of ≥6 on the GDS-15 to identify those with significant depressive symptoms.1 People who screened positive for depressive symptoms were also asked if they were receiving treatment for their low mood.

Data were analyzed on STATA Ver 12. The prevalence of depressive symptoms together with 95% CIs was computed by the exact binomial method. Ethical approval was obtained from the NHS National Research Ethics Service (11/WA/0014).

During the 30-month recruitment period, a total of 1323 consecutive adult patients attended the low vision rehabilitation clinics. Of these, consenting patients 1008 (76.2%) provided complete datasets. The mean (SD) age of consenting patients was 74.4 (16.1) years, 61.7% were women, and 52.8% had a diagnosis of age-related macular degeneration. Overall, the prevalence of significant depressive symptoms, as measured by a GDS-15 score of ≥6, was 43% (95% CI, 40%—46%). And, of those who screened positive for significant depressive symptoms, 74.8% (95% CI, 79.2%—70.7%) were not being treated for their depression. Table 1 (available at www.aaojournal.org) describes the prevalence of significant depressive symptoms according to study location and patient characteristics. Interestingly, a regression analysis indicated that the prevalence of significant depressive symptoms was not related to visual acuity or to the time since sight loss was first identified. Figure 1 describes the prevalence of significant depressive symptoms as a function of time since the onset of sight loss and it seems that depression does not resolve over time. However, because this was a cross-sectional study, we cannot rule out the possible effects of time.

The prevalence of clinically significant depressive symptoms in 43% of those seeking help for sight loss in Britain is striking. To put the findings into perspective, 45% of those with a diagnosis of cancer who are about to undergo chemotherapy have clinically significant depressive features.1 Clearly, people seeking help for their visual problems are a high-risk group for depression, but the fact that three-quarters of those who screened positive were not receiving any form of treatment suggests that depression is being routinely overlooked in this vulnerable group. We are only aware of 2 low vision services in Britain that screen people regularly for depression. People are not getting the help they need.

Addressing a patient’s needs should include more than improving their acuity or other aspect of visual function. Depression is a major cause of disability in its own right; it reduces the effectiveness of low vision rehabilitation interventions, quality of life, and even life expectancy. Depression is a medical condition, treatments can be effective, and screening is relatively straightforward. In Britain, the National Institute for Health and Clinical Excellence (NICE) recommend screening high risk groups by

---

**Reference**

asking a few simple questions which are provided in Table 2 (available at www.aaojournal.org). Alternatively, questionnaires such as the GDS-15 or PHQ-9 are excellent screeners that can be administered in < 5 minutes.

Clinicians providing rehabilitation services want to improve the lives of their patients. We suggest that the introduction of depression screening and referral for treatment where appropriate may be a useful step forward.

CLAIRE L. NOLLETT, BSc1
NATHAN BRAY, MSc1
CATEY BANC, DSc1
ROBIN J. CASTEN, PhD1
RHIANNON T. EDWARDS, PhD2
MARK T. HEGEL, PhD3
SARAH JANIKOUN, MD3
SANDRA E. JUMBE, MSc7
BARBARA RYAN, PhD1
JULIA SHEARN, MPhil3
DANIEL J. SMITH, MD6
MILES STANFORD, MD6
WEN XING, MSc3
TOM H. MARGRAIN, PhD1

1School of Optometry and Vision Sciences, Cardiff University, Cardiff, UK; 2Centre for Health Economics and Medicines Evaluation, School of Healthcare Sciences, Bangor University, Gwynedd, UK; 3NIHR BRC for Ophthalmology at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; 4Department of Psychiatry and Human Behaviour, Sidney Kimmel Medical College at Thomas Jefferson University, Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania; 5Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; 6Ophthalmology (Eye) Department South Wing, St Thomas’ Hospital, London, UK; 7NIHR BRC South East Wales Research Network / Rhwydwaith Ymhwil De Dwyrain Cymru, Cardiff, UK; 8Faculty of Life Sciences and Education, Glyntaff Campus, University of South Wales, Pontypridd, Wales, UK; 9Institute of Health and Wellbeing, University of Glasgow, Mental Health and Wellbeing Research Group, Gartnavel Royal Hospital, Scotland, UK

Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Supported by Guide Dogs (grant no. OR-2009 07b). The sponsor or funding organization had no role in the design or conduct of this research.

Author Contributions:
Conception and design: Nollett, Bray, Bunce, Casten, Edwards, Hegel, Ryan, Shearn, Smith, Stanford, Marnegrain
Analysis and interpretation: Nollett, Bray, Bunce, Smith, Shearn, Marnegrain
Data collection: Nollett, Hegel, Janikoun, Jumbe, Ryan, Shearn, Stanford, Shearn, Marnegrain
Overall responsibility: Nollett, Bray, Bunce, Casten, Edwards, Hegel, Shearn, Jumbe, Ryan, Shearn, Stanford, Xing, Marnegrain

Correspondence:
Tom H. Marnegrain, PhD, School of Optometry and Vision Sciences, Cardiff University, CF 24 4LU, UK. E-mail: marnegrainth@cardiff.ac.uk.

References